Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma

British Journal of Haematology

Volumn 98, Issue 2, 1997, Pages 418-425

  Calasanz, María J ^a   Cigudosa, Juan C ^a   Odero, María D ^d   García Foncillas, Jesen ^a   Marín, Julián ^b   Ardanaz, María T ^c   Rocha, Eduardo ^d   Gullon, Arturo ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Hospital Nuestra Senora de Aranzazu   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d NONE

Author keywords

22q11 abnormalities; Hypodiploidy; Multiple myeloma; Prognostic factors; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 22Q; CHROMOSOME REARRANGEMENT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030825598     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.2443061.x     Document Type: Article

References (29)

1. Alexanian, R. & Dimopoulos, M.A. (1995) Management of multiple myeloma. Seminars in Hematology, 32, 20-30.
2. Barlogie, B., Epstein, J., Selvanayagam, P. & Alexanian, R. (1989) Plasma cell myeloma: new biological insights and advances in therapy. Blood, 73, 865-879.
3. Bataille, R., Boccadoro, M., Klein, B., Durie, B. & Pileri, A. (1992) C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.
4. Bladé, J., López-Guillermo, A., Bosch, F., Cervantes, F., Reverter, J.C., Montserrat, E. & Rozman, C. (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 88, 117-121.
5. Calasanz, M.J., Cigudosa, J.C., Odero, M.D., Ferreira, C., Ardanaz, M.T., Fraife, A., Carrasco, J.L., Solé, F., Cuesta, B. & Gullón, A. (1997) Cytogenetic analysis in 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes, Chromosomes and Cancer, 18, 84-93.
6. Cigudosa, J.C., Calasanz, M.J., Odero, M.D., Prosper, F., Etxaniz, A., Marín, J., Rifón, J., Gullón, A. & Rocha, E. (1994) Cytogenetic data in 41 patients with multiple myeloma: karyotype and other clinical parameters. Cancer Genetics and Cytogenetics, 78, 210-213.
7. Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D.M., Boccadoro, M., Pileri, A. & Dalla-Favera, R. (1994) Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia, 8, 758-767.
8. Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society, 34, 187-220.
9. Dewald, G.W., Kyle, R.A., Hicks, G.A. & Greipp, P.R. (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood, 66, 380-390.
10. Dimopoulos, M.A., Barlogie, B., Smith, T.I., & Alexanian, R. (1991) High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Annals of Internal Medicine, 115, 931-935.
11. Drach, J., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fielg, M., Rothermundt, C., Gsur, A., Jäger, U., Heinz, R., Lechner, K., Ludwig, H. & Huber, H. (1995) Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Research, 55, 3854-3859.
12. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
13. Epstein, J., Hoover, R., Kombluth, J. & Barlogie, B. (1995) Biological aspects of multiple myeloma. Multiple Myeloma (ed. by F. Mandelli), pp. 721-732. Baillière Tindall, London.
14. Facon, T., Menard, J.F., Michaux, J.L., Euller-Ziegler, L., Bernard, J.F., Grosbois, B., Daragon, A., Azais, I., Courouble, Y., Kaplan, G., Laporte, J.P., De Gramont, A., Duclos, B., Leonard, A., Mineur, P., Delannoy, A., Jouet, J.P., Bauters, F. & Monconduit, M., for the Groupe d'Etudes et de Recherche sur le Myélome (GERM) (1995) Prognostic factors in low tumor mass asymptomatic multiple myeloma: a report of 91 patients. American Journal of Hematology, 48, 71-75.
15. García-Sanz, R., Orfao, A., González, M., Moro, M.J., Hernández, J.M., Ortega, F., Borrego, D., Carnero, M., Casanova, F., Jimenez, R., Portero, J.A. & San Miguel, J.F. (1995) Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. British Journal of Haematology, 90, 106-112.
16. Greipp, P.R., Lust, J.A., O'Fallon, W.M., Katzmann, J.A., Witzig, T.E. & Kyle, R.A. (1993) Plasma cell labelling index and β2-microglobulin predict survival independent ot thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382-3387.
17. Kaplan, E. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-485.
18. Karpas, A., Fisher, P. & Swirsky, D. (1982) Human plasmacytoma cell line carrying a Philadelphia chromosome. Science, 216, 997-999.
19. Kyle, R.A. (1994) Why better prognostic factors for multiple myeloma are needed. Blood, 83, 1713-1716.
20. Laï, J.L., Zandecki, M., Mary, J.Y., Bernardi, F., Izydorczyk, V., Flactif, M., Morel, P., Jouet, J.P., Bauters, F. & Facon, T. (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood, 85, 2490-2497.
21. Reibnegger, G., Krainer, M., Herold, M., Ludwig, H., Wachter, H. & Huber, H. (1991) Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Research, 51, 6250-6253.
22. San Miguel, J.F., González, M., Gascón, A., Moro, M.J., Hernández, J.M., Ortega, F., Jimenez, R., Guerras, L., Romero, M., Casanova, F., Sanz, M.A., Sanchez, J., Portero, J.A. & Orfao, A. (1992) Lymphoid subsets and prognostic factors in multiple myeloma. British Journal of Haematology, 30, 305-309.
23. Sawyer, J.R., Waldrom, J.A., Jagannath, S. & Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 41-49.
24. Smadja, N.V., Louvet, C., Isnard, F., Dutel, J.L., Grange, M.J., Varette, C. & Krulik, M. (1995) Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. British Journal of Haematology, 90, 619-624.
25. Taniwaki, M., Nishida, K., Takashima, T., Nakagawa, H., Fujii, H., Tamaki, T., Shimazaki, C., Horiike, S., Misawa, S., Abe, T. & Kashima, K. (1994) Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood, 84, 2283-2290.
26. Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. & Sawyer, J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 4250-4256.
27. Tsuchiya, J., Murakami, H., Kanoh, T., Kosaka, M., Sezaki, T., Mikuni, C., Kawato, M., Takagi, T., Togawa, A., Isobe, T., Suzuki, K., Imamura, Y. & Takatsuki, K., Japan Myeloma Study Group (1994) Ten-year survival and prognostic factors in multiple myeloma. British Journal of Haematology, 87, 832-834.
28. Van den Berghe, H., Louwagie, A., Broeckaert-Van Orsoven, A., David, G., Verwilghem, R., Michaus, J.L. & Sokal, G. (1979) Philadelphia chromosome in human multiple myeloma. Journal of the National Cancer Institute, 63, 11-13.
29. Weh, H.J., Gutensohn, K., Selbach, J., Kruse, R., Wacker-Backhaus, G., Seeger, D., Fiedler, W., Fett, W. & Hossfeld, K. (1993) Karyotype in multiple myeloma and plasma cell leukemia. European Journal of Cancer, 29A, 1269-1273.